The cloudy crystal ball of cost-effectiveness studies

Gerardus W J Frederix; Johan L Severens; Anke M Hövels; Jan A M Raaijmakers; Jan H M Schellens

doi:10.1016/j.jval.2013.06.012

The cloudy crystal ball of cost-effectiveness studies

Gerardus W J Frederix, Johan L Severens, Anke M Hövels, Jan A M Raaijmakers, Jan H M Schellens

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Despite the use of identical clinical trial data (Anastrazole, Tamoxifen, Alone or in Combination for the adjuvant treatment of postmenopausal women with localised hormone receptor-positive breast cancer data), not dependent on differences between countries, the outcome of 11 published cost-effectiveness analyses varied more than 20-fold. The observed wide variation in predicted life-years gained (a parameter derived from clinical trial data) demonstrates that authors used substantially different methods for handling the same data. We therefore consider it to be of utmost importance to strive for standardization of and better guidance for disease-specific modeling in economic evaluations.

Original language	English
Pages (from-to)	1100-2
Number of pages	3
Journal	Value in Health
Volume	16
Issue number	6
DOIs	https://doi.org/10.1016/j.jval.2013.06.012
Publication status	Published - 18 Sept 2013

Keywords

Breast Neoplasms
Cost-Benefit Analysis
Female
Humans
Models, Econometric
Outcome Assessment (Health Care)
Quality-Adjusted Life Years
Journal Article
Research Support, Non-U.S. Gov't

Access to Document

10.1016/j.jval.2013.06.012

Cite this

@article{9f8c8bb926b547b8b2a172e76190ce0f,

title = "The cloudy crystal ball of cost-effectiveness studies",

abstract = "Despite the use of identical clinical trial data (Anastrazole, Tamoxifen, Alone or in Combination for the adjuvant treatment of postmenopausal women with localised hormone receptor-positive breast cancer data), not dependent on differences between countries, the outcome of 11 published cost-effectiveness analyses varied more than 20-fold. The observed wide variation in predicted life-years gained (a parameter derived from clinical trial data) demonstrates that authors used substantially different methods for handling the same data. We therefore consider it to be of utmost importance to strive for standardization of and better guidance for disease-specific modeling in economic evaluations.",

keywords = "Breast Neoplasms, Cost-Benefit Analysis, Female, Humans, Models, Econometric, Outcome Assessment (Health Care), Quality-Adjusted Life Years, Journal Article, Research Support, Non-U.S. Gov't",

author = "Frederix, {Gerardus W J} and Severens, {Johan L} and H{\"o}vels, {Anke M} and Raaijmakers, {Jan A M} and Schellens, {Jan H M}",

note = "Copyright {\textcopyright} 2013, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.",

year = "2013",

month = sep,

day = "18",

doi = "10.1016/j.jval.2013.06.012",

language = "English",

volume = "16",

pages = "1100--2",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - The cloudy crystal ball of cost-effectiveness studies

AU - Frederix, Gerardus W J

AU - Severens, Johan L

AU - Hövels, Anke M

AU - Raaijmakers, Jan A M

AU - Schellens, Jan H M

PY - 2013/9/18

Y1 - 2013/9/18

N2 - Despite the use of identical clinical trial data (Anastrazole, Tamoxifen, Alone or in Combination for the adjuvant treatment of postmenopausal women with localised hormone receptor-positive breast cancer data), not dependent on differences between countries, the outcome of 11 published cost-effectiveness analyses varied more than 20-fold. The observed wide variation in predicted life-years gained (a parameter derived from clinical trial data) demonstrates that authors used substantially different methods for handling the same data. We therefore consider it to be of utmost importance to strive for standardization of and better guidance for disease-specific modeling in economic evaluations.

AB - Despite the use of identical clinical trial data (Anastrazole, Tamoxifen, Alone or in Combination for the adjuvant treatment of postmenopausal women with localised hormone receptor-positive breast cancer data), not dependent on differences between countries, the outcome of 11 published cost-effectiveness analyses varied more than 20-fold. The observed wide variation in predicted life-years gained (a parameter derived from clinical trial data) demonstrates that authors used substantially different methods for handling the same data. We therefore consider it to be of utmost importance to strive for standardization of and better guidance for disease-specific modeling in economic evaluations.

KW - Breast Neoplasms

KW - Cost-Benefit Analysis

KW - Female

KW - Humans

KW - Models, Econometric

KW - Outcome Assessment (Health Care)

KW - Quality-Adjusted Life Years

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/j.jval.2013.06.012

DO - 10.1016/j.jval.2013.06.012

M3 - Article

C2 - 24041361

SN - 1098-3015

VL - 16

SP - 1100

EP - 1102

JO - Value in Health

JF - Value in Health

IS - 6

ER -

The cloudy crystal ball of cost-effectiveness studies

Abstract

Keywords

Access to Document

Fingerprint

Cite this